Recruiting Epilepsy Studies in New York
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
Methylphenidate (MPH) is a stimulant, FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD). It is unknown, however, if stimulants would be of benefit for memory and thinki...
RNS System LGS Feasibility Study
To generate preliminary safety and effectiveness data for brain-responsive neurostimulation of thalamocortical networks as an adjunctive therapy in reducing the frequency of generalized seizures in in...
About Epilepsy Clinical Trials in New York
Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. It affects about 50 million people worldwide. Treatment includes antiseizure medications, surgery, and neurostimulation devices.
There are currently 2 epilepsy clinical trials recruiting participants in New York, NEW%20YORK. These studies are seeking a combined 250 participants. Research is being sponsored by VA Office of Research and Development, NeuroPace. Clinical trial participation is free and participants receive study-related medical care at no cost.
Epilepsy Clinical Trials in New York — FAQ
Are there epilepsy clinical trials in New York?
Yes, there are 2 epilepsy clinical trials currently recruiting in New York, NEW%20YORK. Browse the studies on this page to find one that fits.
How do I join a clinical trial in New York?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you about next steps.
Are clinical trials in New York free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New York studies also compensate for your time and travel.
What epilepsy treatments are being tested?
The 2 active trials in New York are testing new therapies including novel drugs, biologics, and treatment approaches for epilepsy.
Data updated March 2, 2026 from ClinicalTrials.gov